Detailed CagriSema data challenge amylin muscle-sparing mechanism

As one of the rising stars in obesity therapeutics this year, the target amylin has sparked several major pharma deals. That enthusiasm has been driven by the potential for amylin agonists to not only be more tolerable than incretin-based therapies, but also to generate higher-quality weight loss that spares muscle tissue. 

The most recent data from the Phase III REDEFINE-1 trial of CagriSema cagrilintide/semaglutide from Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) challenge whether amylin is muscle-sparing at all. Indeed, the data suggest amylin may perform numerically worse than GLP-1R agonists in terms of driving preferential weight loss from fat vs. lean mass...